Symptom burden and its functional impact in patients with “symptomatic” relapsed or refractory multiple myeloma

Purpose Relapsed or refractory multiple myeloma (RRMM) is labeled “symptomatic” based on laboratory values, but not relevant to quantitative measure of patient’s perspectives. This study aimed to describe symptom burden, health status, and quality of life in RRMM patients. Methods The cross-sectiona...

Full description

Saved in:
Bibliographic Details
Published in:Supportive care in cancer 2021, Vol.29 (1), p.467-475
Main Authors: Kamal, Mona, Wang, Xin Shelley, Shi, Qiuling, Zyczynski, Teresa M., Davis, Catherine, Williams, Loretta A., Lin, Hui-Kai, Garcia-Gonzalez, Araceli, Cleeland, Charles S., Orlowski, Robert
Format: Article
Language:English
Subjects:
Aged
Cross-Sectional Studies
Female
Humans
Male
Medicine
Medicine & Public Health
Multiple myeloma
Multiple Myeloma - drug therapy
Nursing
Nursing Research
Oncology
Original Article
Pain Medicine
Patient Reported Outcome Measures
Patients
Physical fitness
Quality of life
Quality of Life - psychology
Rehabilitation Medicine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Relapsed or refractory multiple myeloma (RRMM) is labeled “symptomatic” based on laboratory values, but not relevant to quantitative measure of patient’s perspectives. This study aimed to describe symptom burden, health status, and quality of life in RRMM patients. Methods The cross-sectional study included 184 MM patients (141 RRMM cases and 43 MM patients on follow-up without diagnosis/treatment of RRMM disease as controls), while 64 RRMM patients also provided longitudinal patient-reported outcomes (PROs) data. Symptomatic status was based on clinical measures of disease activity. PROs included the MD Anderson Symptom Inventory multiple myeloma module (MDASI-MM), single-item quality of life (SIQOL), and EuroQol-5D (EQ-5D). Wilcoxon rank test and effect size were used for comparisons. Regression models were used to describe symptom trajectory and to identify predictors of high symptom burden during 3 months of RRMM therapy. Results Most patients were clinically identified as symptomatic (93%). RRMM patients tended to report more severe symptoms, with significantly lower QOL scores and more severe fatigue, poor appetite, and lower enjoyment of life compared with controls (all p  
ISSN:0941-4355
1433-7339
DOI:10.1007/s00520-020-05493-y